Weaker prospects for pharmaceutical big Novo Nordisk A/S NVS have prompted Denmark’s financial ministry to chop its 2025 GDP forecast, now anticipating simply 1.4% development, down 1.5 share factors from Might’s projection.
Progress is seen rebounding to 2.1% in 2026, up 0.7 factors. Employment remains to be rising and inflation is projected to remain beneath 2%. The ministry mentioned U.S. tariff hikes will additional weigh on exports and international exercise, whereas an EU-U.S. commerce framework reduces uncertainty round gross sales phrases.
Additionally Learn: New Weight problems Medicine Might See Premium Pricing Undermined By Underwhelming Knowledge
Denmark’s development outlook is being formed by shopper energy, exports, and Novo Nordisk’s trajectory. Rising family demand, boosted by wage positive factors, tax cuts, and excessive employment, is supporting personal consumption.
Reuters famous Denmark’s sturdy 2024 development was amongst Europe’s highest, with Novo Nordisk alone contributing one-fifth of employment positive factors. However headwinds are mounting.
U.S. tariffs, for instance, dragged exports sharply decrease in early 2025, chopping forecast development to 0.9% from 4.3% in Might.
In the meantime, Novo Nordisk—maker of Wegovy and Ozempic—introduced a international hiring freeze and lowered its 2025 gross sales forecast to eight–14% development, down from 13–21%, citing slower uptake of branded GLP-1 medication and rising competitors from Eli Lilly and compounded alternate options.
Nonetheless, Denmark’s financial system ministry raised its 2026 GDP outlook to 2.1%, pointing to stronger personal and public spending.
Value Motion: NVO inventory is up 0.04% at $56.14 on the final examine on Friday.
Learn Subsequent:
Picture: Shutterstock
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
